Skip to main content

Table 1 Efficacy data of rituximab monotherapy depending on MZL subtypes

From: A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

MZL subtype Number of patients OR (%) CR (%)
EMZL [11] 112 73 45
[12] 138 78 56
SMZL [11] 122 92 58
NMZL [11] 3 33 0
  1. MZL marginal zone lymphoma, EMZL extranodal marginal zone lymphoma, SMZL splenic marginal zone lymphoma, NMZL nodal marginal zone lymphoma, OR overall response, CR complete response